β-blockers for infantile hemangiomas: A single-institution experience

Julie Blatt, Dean S. Morrell, Scott Buck, Carlton Zdanski, Stuart Gold, Joseph Stavas, Cynthia Powell, Craig N. Burkhart

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers. Of 302 children with hemangiomas seen at the University of North Carolina from 2008 through 2010, 15.6% were treated with oral propranolol alone, 5.6% with topical timolol (a propranolol derivative) alone, and 2.3% with both. The use of these agents increased over time from 7% of patients seen in 2008 to 54% of patients first seen in 2010. Starting doses of propranolol ranged from 0.25 to 1 mg/kg/d, with target doses of 1 to 4 mg/kg/d. Serious side effects, noted in 6/54 (10.9%) patients, included somnolence, bradycardia, hypotension, hypoglycemia, and mottling of extremities.The authors confirm the variation in use of propranolol for vascular lesions and extend experience with timolol. They suggest daily home monitoring of patients for the first 2 weeks of initiating or increasing doses. Frequent feeding of infants and young children on this drug is recommended.

Original languageEnglish
Pages (from-to)757-763
Number of pages7
JournalClinical Pediatrics
Volume50
Issue number8
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Hemangioma
Propranolol
Timolol
Physiologic Monitoring
Bradycardia
Hypoglycemia
Hypotension
Blood Vessels
Extremities
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Blatt, J., Morrell, D. S., Buck, S., Zdanski, C., Gold, S., Stavas, J., ... Burkhart, C. N. (2011). β-blockers for infantile hemangiomas: A single-institution experience. Clinical Pediatrics, 50(8), 757-763. https://doi.org/10.1177/0009922811405517

β-blockers for infantile hemangiomas : A single-institution experience. / Blatt, Julie; Morrell, Dean S.; Buck, Scott; Zdanski, Carlton; Gold, Stuart; Stavas, Joseph; Powell, Cynthia; Burkhart, Craig N.

In: Clinical Pediatrics, Vol. 50, No. 8, 08.2011, p. 757-763.

Research output: Contribution to journalArticle

Blatt, J, Morrell, DS, Buck, S, Zdanski, C, Gold, S, Stavas, J, Powell, C & Burkhart, CN 2011, 'β-blockers for infantile hemangiomas: A single-institution experience', Clinical Pediatrics, vol. 50, no. 8, pp. 757-763. https://doi.org/10.1177/0009922811405517
Blatt, Julie ; Morrell, Dean S. ; Buck, Scott ; Zdanski, Carlton ; Gold, Stuart ; Stavas, Joseph ; Powell, Cynthia ; Burkhart, Craig N. / β-blockers for infantile hemangiomas : A single-institution experience. In: Clinical Pediatrics. 2011 ; Vol. 50, No. 8. pp. 757-763.
@article{2b1ed8d61b06412a8a0896c57009d177,
title = "β-blockers for infantile hemangiomas: A single-institution experience",
abstract = "Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers. Of 302 children with hemangiomas seen at the University of North Carolina from 2008 through 2010, 15.6{\%} were treated with oral propranolol alone, 5.6{\%} with topical timolol (a propranolol derivative) alone, and 2.3{\%} with both. The use of these agents increased over time from 7{\%} of patients seen in 2008 to 54{\%} of patients first seen in 2010. Starting doses of propranolol ranged from 0.25 to 1 mg/kg/d, with target doses of 1 to 4 mg/kg/d. Serious side effects, noted in 6/54 (10.9{\%}) patients, included somnolence, bradycardia, hypotension, hypoglycemia, and mottling of extremities.The authors confirm the variation in use of propranolol for vascular lesions and extend experience with timolol. They suggest daily home monitoring of patients for the first 2 weeks of initiating or increasing doses. Frequent feeding of infants and young children on this drug is recommended.",
author = "Julie Blatt and Morrell, {Dean S.} and Scott Buck and Carlton Zdanski and Stuart Gold and Joseph Stavas and Cynthia Powell and Burkhart, {Craig N.}",
year = "2011",
month = "8",
doi = "10.1177/0009922811405517",
language = "English",
volume = "50",
pages = "757--763",
journal = "Clinical Pediatrics",
issn = "0009-9228",
publisher = "SAGE Publications Inc.",
number = "8",

}

TY - JOUR

T1 - β-blockers for infantile hemangiomas

T2 - A single-institution experience

AU - Blatt, Julie

AU - Morrell, Dean S.

AU - Buck, Scott

AU - Zdanski, Carlton

AU - Gold, Stuart

AU - Stavas, Joseph

AU - Powell, Cynthia

AU - Burkhart, Craig N.

PY - 2011/8

Y1 - 2011/8

N2 - Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers. Of 302 children with hemangiomas seen at the University of North Carolina from 2008 through 2010, 15.6% were treated with oral propranolol alone, 5.6% with topical timolol (a propranolol derivative) alone, and 2.3% with both. The use of these agents increased over time from 7% of patients seen in 2008 to 54% of patients first seen in 2010. Starting doses of propranolol ranged from 0.25 to 1 mg/kg/d, with target doses of 1 to 4 mg/kg/d. Serious side effects, noted in 6/54 (10.9%) patients, included somnolence, bradycardia, hypotension, hypoglycemia, and mottling of extremities.The authors confirm the variation in use of propranolol for vascular lesions and extend experience with timolol. They suggest daily home monitoring of patients for the first 2 weeks of initiating or increasing doses. Frequent feeding of infants and young children on this drug is recommended.

AB - Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers. Of 302 children with hemangiomas seen at the University of North Carolina from 2008 through 2010, 15.6% were treated with oral propranolol alone, 5.6% with topical timolol (a propranolol derivative) alone, and 2.3% with both. The use of these agents increased over time from 7% of patients seen in 2008 to 54% of patients first seen in 2010. Starting doses of propranolol ranged from 0.25 to 1 mg/kg/d, with target doses of 1 to 4 mg/kg/d. Serious side effects, noted in 6/54 (10.9%) patients, included somnolence, bradycardia, hypotension, hypoglycemia, and mottling of extremities.The authors confirm the variation in use of propranolol for vascular lesions and extend experience with timolol. They suggest daily home monitoring of patients for the first 2 weeks of initiating or increasing doses. Frequent feeding of infants and young children on this drug is recommended.

UR - http://www.scopus.com/inward/record.url?scp=80052518387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052518387&partnerID=8YFLogxK

U2 - 10.1177/0009922811405517

DO - 10.1177/0009922811405517

M3 - Article

C2 - 21525081

AN - SCOPUS:80052518387

VL - 50

SP - 757

EP - 763

JO - Clinical Pediatrics

JF - Clinical Pediatrics

SN - 0009-9228

IS - 8

ER -